A Message From Weiss Ratings

Dear Reader,

I don’t trust Sam Altman at all …

And neither should you.

Because my research tells me he is hiding something …

Something so potent, so revealing …

It could spark the biggest monetary crisis of our lifetime.

Worse than the Dot-Com Crash …

The housing market collapse …

Even the Great Depression …

COMBINED.

That’s why I suspect he’s using every tool at his disposal to keep this from getting out.

But on Dec. 18, around 4 p.m. …

He will be forced to reveal a document that’s currently confidential.

When he does, it will immediately trigger a $40 trillion wealth shift …

Altman himself has even said …

“Someone is going to lose a phenomenal amount of money … And a lot of people are going to make a phenomenal amount of money.”

To make sure you’re on the right side of this divide, click here.

Nilus Mattive

P.S. Look, if you wait for OpenAI to go public before you act … you’ll be too late.

Altman is expected to drop this bombshell on Dec. 18 …

Weeks before a potential IPO.

So please, don’t hesitate.

Watch this video to find out how you can protect yourself.

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

By Bridget Bennett. Originally Published: 10/26/2026.

The S&P 500 remains in a confirmed uptrend, yet a large portion of the market isn't along for the ride. Money continues to crowd into the same mega-cap leaders, while plenty of solid companies trade below their 50-day moving averages even as their earnings outlooks hold up.

That gap between price and fundamentals is where opportunity tends to hide. When investors chase a handful of names, everything else can get marked down—sometimes for reasons that don't survive closer scrutiny.

Four stocks fit that profile: a Latin American e-commerce leader, a GLP-1 drugmaker trading at a discount, a government software provider shaking off AI fears and a speculative biotech awaiting a major regulatory decision. Each has been knocked down, but each also has something that could change the conversation.

The real question isn't whether these stocks are cheap. It's whether the market has priced them for a future worse than the one actually unfolding.

Market Concentration Leaves Quality Stocks Trading at a Discount

The eight largest stocks in the S&P 500 now account for more than 35% of the index's total market value, according to Alexander Green, chief investment strategist at The Oxford Club. Investors continue to pile into Microsoft (NASDAQ: MSFT), NVIDIA (NASDAQ: NVDA), Oracle (NYSE: ORCL) and the other hyperscalers—the cloud giants funding the AI buildout.

That leaves the other 492 stocks, along with smaller and foreign companies, overlooked. In Green's view, many have earnings prospects that their share prices don't yet reflect, and share prices tend to follow earnings over time. The backdrop is supportive, with a solid economy, full employment and a consensus estimate Green cites of roughly 30% third-quarter profit growth.

Post-Midterm Seasonality Gives Beaten-Down Stocks a Historical Tailwind

The calendar adds another potential tailwind. The nine months after a midterm election, covering the fourth quarter and the following two quarters, have historically been a strong stretch for stocks—a pattern money manager Ken Fisher calls the "midterm miracle." Green puts the average gain at about 19.5%, roughly double the S&P 500's typical annual return of near 10%.

Party control appears to matter little. Whether there is gridlock or a sweep, markets tend to rally once policy uncertainty clears. History is no guarantee, but it keeps the door open for beaten-down names with improving earnings.

Latin American E-Commerce and GLP-1 Drugs Bring Global Growth at a Discount

The United States makes up about 25% of the global economy and 4.2% of the world's population, according to Green, who spent his first 16 years on Wall Street helping Americans invest abroad. International stocks look cheap after years of lagging, and they can add currency diversification if the dollar weakens.

MercadoLibre (NASDAQ: MELI), often called the Amazon of Latin America, dominates e-commerce in a fragmented region where online shopping is still gaining ground. Green argues that its position there is stronger than Amazon's (NASDAQ: AMZN) in the United States. The stock faltered on margin concerns tied to spending for long-term growth, a worry he considers overblown. Evidence that the spending is translating into earnings could shift sentiment, making margins the key metric to watch.

Novo Nordisk (NYSE: NVO), maker of the GLP-1 weight-loss drug Wegovy, slid after multiple earnings misses and rising competition from category leader Eli Lilly (NYSE: LLY).

Green sees room for both companies. Insurers and governments are expanding coverage as these drugs are linked to lower rates of heart disease, diabetes and other obesity-related illnesses. In addition, patients who stop taking the drugs often regain the weight.

He describes the stock as trading below 10 times earnings with a large dividend yield. Pipeline approvals and earnings surprises could change the story.

The Oxford Club recently added the stock back to its portfolio after an earlier position was stopped out, with what Green described as a 123% gain.

AI Fears Overshoot the Fundamentals in Government Software

Tyler Technologies (NYSE: TYL) sells software that helps local, state, federal and foreign governments handle everything from building permits to appointment scheduling. Government contracts are difficult to win and difficult to lose, which helps keep earnings unusually stable.

The stock was swept into this year's software-as-a-service (SaaS) sell-off on fears that AI would make such platforms obsolete. Green calls that concern overblown, arguing that AI should augment Tyler's tools rather than replace them—a case Salesforce (NYSE: CRM) CEO Marc Benioff has made about his own business.

Shares have bounced in the short term but remain in a longer-term downtrend. Rising earnings could turn the bounce into a sustained trend.

A Pre-Revenue Biotech Offers a Speculative Bet on an FDA Catalyst

Summit Therapeutics (NASDAQ: SMMT) is the high-risk name on the list. The pre-revenue biotech's lead lung cancer drug has shown strong results in Chinese trials, and Green expects a U.S. FDA decision in mid-November, with additional trial data from China due in the fourth quarter. Approval would put it in competition with Merck (NYSE: MRK) and its category-leading Keytruda.

Shares have traded as high as about $33 over the past 18 months before falling below $15, according to Green, who notes that famed biotech investors the Baker Brothers hold a large stake.

He suggests taking a small position and selling at least half on a significant pop. For traders, he floated November call options, which would pay off only if the catalyst delivers.

Earnings and Hard Catalysts Could Close the Gap for Beaten-Down Stocks

Margin worries at MercadoLibre, earnings misses at Novo Nordisk, the AI scare around Tyler Technologies and the regulatory wait at Summit Therapeutics knocked these four stocks down. What connects them is a market pricing in disappointment that the fundamentals may not deliver. None of these setups depends on the mega-cap leaders stumbling. They depend on earnings and catalysts actually showing up.

The upside is a rerating as results improve, potentially aided by the post-midterm pattern. The risk is that skepticism proves justified through thinner margins, further share loss to Eli Lilly, renewed software pressure or an FDA rejection that could send Summit sharply lower.

Green manages that risk with trailing stops. With a 25% stop on a stock bought at $20, the exit starts at $15 and rises with the price, reaching $22.50 at $30. Profits can run while losses remain limited.

Stay focused on earnings revisions and catalyst dates, because those are what can move beaten-down stocks back toward fair value.

Green and his team at The Oxford Club have also published a special report on Phase 2 of the AI story, focused on companies the market hasn't caught onto yet. Get Alexander Green's special report on the next phase of AI stocks.

A Message From Brownstone Research

Jeff Brown is the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years in advance. He's now predicting Elon Musk is about to open a new wealth window by October 30. Click here to see the details or read more below because the last three times this window opened, those who acted had a chance to walk away with generational wealth.

Dear Reader,

Have you seen this Elon Musk new project?

He called it "the most epic AI project in history…"

Because it could help him secure 50 times MORE computing power than the entire rest of the world.

This is all part of Elon Musk's $320 trillion masterplan…

A blueprint to completely dominate the entire AI industry.

And I'm pretty sure this is keeping executives at Amazon, Microsoft, and Google up at night.

But what does this mean for you?

Well, Elon is predicting this could be 180 times bigger than the SpaceX IPO.

That IPO minted 4,400 millionaires overnight.

If this is 180 times bigger…

Just imagine how many more Americans will become millionaires.

Will you be one of them?

Or will you just watch others get rich from the sidelines?

Click here to see the details and decide for yourself.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?

Authored by Jeffrey Neal Johnson. Posted: 10/13/2026.

Micron Technology, Inc. (NASDAQ: MU) recently saw its share price decline amid concerns about advances in Chinese memory technology. Despite the recent pressure, Micron Technology retains a year-to-date gain of more than 220%. The divergence between the company's underlying financial performance and the market's immediate reaction creates a compelling setup for investors evaluating the longevity of the memory cycle.

A mixture of international headlines triggered the sell-off, prompting concerns about future pricing power and potential capacity gluts. Assessing whether these threats carry long-term weight or are merely a sentiment-driven blip requires looking past the noise and examining the underlying supply-and-demand dynamics of the semiconductor market.

Market Contagion: Separating Headline Noise From Data

Markets do not like uncertainty, and memory chip stocks are notoriously sensitive to any hint of future oversupply. The catalyst for the recent contraction largely stems from China-based ChangXin Memory Technologies (CXMT). The company announced developmental progress on a denser 4F square DRAM architecture, explicitly targeting the high-end server memory segment. Combined with a localized union strike authorization at Micron's Taoyuan manufacturing operations in Taiwan, the headlines created a difficult environment for institutional positioning.

Contrasting these fears with actual earnings performance reveals a possible disconnect. Micron Technology reported fiscal fourth-quarter revenue of $54.23 billion, up about 379% year over year. Adjusted earnings topped $33 per share. These results reflect a business operating at exceptionally strong levels of profitability. The market reaction appears to reflect anxieties about events that may not materialize for years. The trailing price-to-earnings ratio sits around 12.60, while the discounted forward multiple is approximately 5.37, indicating skepticism about the durability of peak-cycle earnings.

Lab Leak: Projecting China's 2026 Memory Goals

Understanding the details of the ChangXin Memory Technologies announcement helps separate genuine competitive risks from geopolitical noise. The company claims to have made progress in developing a 4F square DRAM design, which theoretically increases storage density. Its goal is to launch a server memory product based on this architecture by the end of 2026.

The timeline is the critical variable. The 4F square architecture has not yet demonstrated commercial-scale production, despite CXMT's plans to introduce a product before year-end. The memory market has high barriers to entry, including yield rates, packaging reliability and enterprise-grade validation. A state-backed competitor could eventually pressure long-term pricing floors across the DRAM market. However, a production target set for late 2026 does not necessarily alter the current supply-and-demand imbalance in the high-end server memory market. Projecting theoretical capacity additions onto current valuations can contribute to mispricing, particularly in a sector driven by immediate artificial intelligence (AI) hardware requirements.

Collateral Damage: Contagion in the Memory Oligopoly

The market reaction suggests that the recent news contributed to broad industry selling rather than a reassessment of Micron alone. SK hynix Inc. (NASDAQ: SKHY) fell more than 4% during the same trading window. Equipment manufacturers also caught the downdraft, with several semiconductor equipment stocks declining.

When the entire supply chain sells off simultaneously, investors may be pricing in a sector-wide threat of future oversupply and potential margin compression. Memory markets are inherently cyclical, and Wall Street remains highly attentive to any signal that the current upcycle may be peaking. Adding to the sector-wide pressure, supply chain reports suggest that equipment providers could raise prices by roughly 10% for competitors such as Samsung (OTCMKTS: SSNLF) and SK hynix. While this is not directly aimed at all memory makers, it signals broader capital expenditure inflation that could squeeze margins across the manufacturing sector.

Friction Points: Insider Sales and Labor Disputes

Beyond potential future supply threats, a few immediate friction points warrant attention. A local union at Micron's Taoyuan, Taiwan, manufacturing hub officially authorized a strike over bonus structures. No strike date has been announced. While labor disputes are common in heavy manufacturing, Taiwan is a critical production center. Any prolonged work stoppage could create a localized risk to production output and customer delivery commitments.

Micron Technology also recently agreed to a $600 million settlement regarding a Netlist patent dispute. Under the agreement, Micron will pay $30 million per quarter over five years beginning in the fourth quarter of 2026, rather than making a single $600 million payment. This creates a cash headwind for future free cash flow models. Coupled with recent insider sales totaling roughly $90 million over the trailing 90 days, including shares sold by Chief Executive Officer Sanjay Mehrotra, it is understandable why some institutional players may have opted to secure profits after a historic run-up. While insider selling does not inherently signal fundamental weakness, it can exacerbate downward momentum during periods of elevated volatility.

Demand Visibility and Strategic Buybacks

Balancing the speculative risks against the fundamental data paints a different picture. Micron Technology has already secured customer commitments covering more than 75% of its fiscal 2027 output, with customers actively discussing 2028 allocations. A potential Chinese product arriving in late 2026 would enter a market where most capacity is already spoken for by major enterprise clients.

The profitability metrics are equally compelling. Micron's fiscal 2026 net margin reached approximately 63.8%, reflecting its exceptionally strong earnings performance. Because Wall Street is pricing in a cyclical peak, the stock trades at a compressed forward multiple of approximately 5.4. This presents an interesting valuation disconnect. Management appears to recognize this disparity and recently authorized an approximately $35 billion share repurchase program. A buyback of this scale signals internal confidence in sustained free cash flow generation and could provide a structural floor for Micron's stock price.

Investors monitoring the memory space may want to watch upcoming earnings reports for signs of stability in memory contract pricing and the trajectory of gross margins. If pricing leverage holds firm against the geopolitical noise, the current pullback could represent a structural mispricing rather than the beginning of a prolonged cyclical downturn.